Amgen

Amgen
Coolcaesar · CC BY-SA 3.0 · source
Name	Amgen
Type	Public
Traded as	NASDAQ: AMGN
Industry	Biotechnology
Founded	1980
Founder	George Rathmann, Bill Bowes, Frank Callahan, Dan Gifford, Kathryn Shaw, Joe Rubinfeld, Vivian Smith
Headquarters	Thousand Oaks, California
Key people	Robert A. Bradway, David M. Reese

Amgen is a multinational biotechnology company that has been a pioneer in the field of biologics and therapeutic proteins, with a strong presence in the global pharmaceutical industry, collaborating with companies like Pfizer, Merck & Co., and Johnson & Johnson. Founded in 1980 by a group of visionary scientists and entrepreneurs, including George Rathmann and Bill Bowes, Amgen has its headquarters in Thousand Oaks, California, and has established itself as a leader in the development of innovative medicines, often working with renowned research institutions like Stanford University and Massachusetts Institute of Technology. Amgen's commitment to biomedical research has led to the development of groundbreaking treatments for various diseases, including cancer, inflammatory disorders, and cardiovascular disease, with support from organizations like the National Institutes of Health and the American Cancer Society. The company's success can be attributed to its strong partnerships with other industry leaders, such as GlaxoSmithKline, AstraZeneca, and Eli Lilly and Company.

● History

Amgen's history dates back to 1980, when it was founded by a group of entrepreneurs, including George Rathmann, Bill Bowes, and Frank Callahan, with the goal of developing innovative biotechnology products, often in collaboration with academic institutions like University of California, Los Angeles and Harvard University. The company's early years were marked by significant milestones, including the development of its first product, Epogen (epoetin alfa), which was approved by the US Food and Drug Administration in 1989, and has been used in conjunction with treatments developed by companies like Roche Holding and Novartis. Amgen's success with Epogen was followed by the development of other blockbuster products, including Neupogen (filgrastim) and Aranesp (darbepoetin alfa), which have been used to treat patients with conditions like anemia and neutropenia, often in combination with therapies developed by Bristol-Myers Squibb and Sanofi. Throughout its history, Amgen has established partnerships with other industry leaders, such as Abbott Laboratories and Wyeth, to develop and commercialize new products, and has worked closely with regulatory agencies like the European Medicines Agency and the World Health Organization.

● Products

Amgen's product portfolio includes a range of innovative medicines that have been developed to treat various diseases, including cancer, inflammatory disorders, and cardiovascular disease, often in collaboration with companies like Celgene and Gilead Sciences. Some of the company's key products include Enbrel (etanercept), which is used to treat rheumatoid arthritis and other inflammatory disorders, and has been used in combination with treatments developed by Pfizer and Merck & Co.. Amgen has also developed Prolia (denosumab), which is used to treat osteoporosis and prevent bone fractures, and has been used in conjunction with therapies developed by Eli Lilly and Company and Novartis. Additionally, the company has developed Xgeva (denosumab), which is used to prevent skeletal-related events in patients with bone metastases from cancer, and has worked with organizations like the American Society of Clinical Oncology and the National Comprehensive Cancer Network to promote its use.

● Research and Development

Amgen's research and development efforts are focused on developing innovative medicines that address significant unmet medical needs, often in collaboration with academic institutions like Stanford University and Massachusetts Institute of Technology. The company has a strong pipeline of products in development, including biosimilars and biologics that target various diseases, such as cancer, inflammatory disorders, and cardiovascular disease, and has worked with companies like GlaxoSmithKline and AstraZeneca to develop new treatments. Amgen's research and development efforts are supported by its state-of-the-art research facilities, including its headquarters in Thousand Oaks, California, and its research centers in Cambridge, Massachusetts and San Francisco, California, which have collaborated with institutions like University of California, San Francisco and Harvard University. The company has also established partnerships with other industry leaders, such as Pfizer and Merck & Co., to develop and commercialize new products, and has worked closely with regulatory agencies like the US Food and Drug Administration and the European Medicines Agency.

● Corporate Affairs

Amgen's corporate affairs are managed by its executive leadership team, which is led by Robert A. Bradway, the company's chairman and chief executive officer, who has worked with other industry leaders like Johnson & Johnson and Eli Lilly and Company. The company's board of directors includes a range of experienced leaders from the biotechnology and pharmaceutical industries, including François Nader, former president and chief executive officer of NPS Pharmaceuticals, and R. Sanders Williams, former dean of the Duke University School of Medicine. Amgen is committed to corporate social responsibility and has established a range of programs to support the communities in which it operates, including its Amgen Foundation, which provides funding for science education and healthcare initiatives, and has worked with organizations like the American Red Cross and the United Way. The company has also established partnerships with other organizations, such as the World Health Organization and the Bill and Melinda Gates Foundation, to support global health initiatives.

● Financial Information

Amgen's financial performance is strong, with revenues of over $23 billion in 2020, and a market capitalization of over $100 billion, making it one of the largest biotechnology companies in the world, with a significant presence in the global pharmaceutical industry, alongside companies like Pfizer, Merck & Co., and Johnson & Johnson. The company's financial success is driven by its portfolio of innovative medicines, which generate significant revenues from sales in the United States and internationally, often in collaboration with companies like GlaxoSmithKline and AstraZeneca. Amgen's financial performance is also supported by its strong research and development pipeline, which is expected to drive future growth and innovation, and has been recognized by industry leaders like Bloomberg and Forbes. The company has a strong track record of delivering value to its shareholders, with a dividend yield of over 2% and a history of share price growth, and has been recognized as one of the best places to work by organizations like Fortune magazine and the Human Rights Campaign.